Đang chuẩn bị liên kết để tải về tài liệu:
Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: Clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is an uncommon primary liver malignancy and little known about the clinical and imaging characteristics of cHCC-CC. We aim to define the demographics, imaging features of cHCC-CC on contrast-enhanced ultrasound (CEUS) and contrast-enhanced computed tomography (CT) in this study. |

TÀI LIỆU LIÊN QUAN

Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: A propensity score matching analysis

Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: A single-arm meta-analysis based on prospective studies

Synchronous cancers of gallbladder carcinoma and combined hepatocellular cholangiocarcinoma: An unusual case and literature review

Role of autophagy-related protein in the prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgical resection

Effect of liver transplantation in combined hepatocellular and cholangiocellular carcinoma: A case series

The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas

Treatment outcomes of unresectable hepatocellular carcinoma by transarterial chemoembolisation combined with radiofrequency ablation

Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: Results of a single-center retrospective case control study

The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

A novel combined systemic inflammationbased score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.